Main Article Content

Abstract

A B S T R A C T
Introduction Diffuse large B cell lymphoma (DLBCL) is the most common type of
non-Hodgkin lymphoma among B cell lymphomas. The interaction of tumor cells
with their microenvironment (tumor microenvironment, TME) leads to progressivity
of malignancy. CD163 + macrophages known as components of TME. Nuclear factor
of activated T cell (NFATc1) and MYC are important transcription factors in
malignant transformation and progression. Therapeutic strategies were fast
developed, nevertheless, efforts to decrease DLBCL morbidity and mortality are
unsatisfied, therefore,new markers for prognosis and or therapeutic options of the
patients are necessary. This study was aimed to investigate NFATc1 expression in
DLBCL and its TME. Methods: Thirty-two paraffin blocks were selected then
immunostained for expression of NFATc1, MYC, and CD163. Clinopathologic data
i.e. ages, gender, and proliferation index Ki-67 were obtained. Data was analyzed
by statistics Result: Positive expression of CD163 and NFATc1 was among 55%
and 45% of cases respectively. All DLBCL cases in this study were non-GCB
subtype and more patients were under 60 years (66%). Positive expression of
CD163 was higher in males (69%) and in patients under 60 years (63%). Tissues
positive for both NFATc1 and CD163 was observed higher among males and
patients under 60 years. Conclusion: NFATc1 may affect development and or
progression of certain subsets of DLBCL non-GCB subtype.

Keywords

Diffuse large B cell lymphoma NFATc1 MYC PD-L1 CD163

Article Details

How to Cite
Murti, K., Muslina, M., Kartika, I., Hidayat, R., & Amalia, E. (2021). Nfatc1 and Tumor Associated Macrophages Affect Progression of Certain Subsets of Diffuse Large B Cell Lymphoma Non-Gcb Subtypes. Bioscientia Medicina : Journal of Biomedicine and Translational Research, 5(2), 345-353. https://doi.org/10.32539/bsm.v5i2.136